TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
October 31, 2024 4:06 PM EDT
Citi Removes Two names from 90-Day Catalyst Watch Lists
Tandem Diabetes (NASDAQ:
TNDM) Removed from 90-Day Downside Catalyst Watch List: "With our 3Q24 Preview (10/1/24), we opened a 90-day Negative Catalyst Watch on TNDM. The thesis was: 1) survey results suggested ~flat Tandem share of new patient starts in the U.S. in the 3Q24E; 2) while Mobi prescriptions were increasing, it...
More
October 30, 2024 4:16 PM EDT
Goldman Sachs analyst David Roman reiterated a Buy rating and $80.00 price target on Edwards Lifesciences (NYSE: EW).
The analyst comments "Overall, we think confirmatory results for the full cohort of TRISCEND II was broadly expected by investors we have spoken... More
October 30, 2024 4:03 PM EDT
BofA Securities analyst Travis Steed reiterated a Neutral rating and $75.00 price target on Edwards Lifesciences (NYSE: EW).
The analyst comments "On Wednesday EW hosted a TMTT investor event after Evoque pivotal data were presented. See TRISCEND II at TCT report for our initial take on the data. We go over the key... More
